Physician profile
Unknown Cherry
NPI 1689659377
$2,060.64
in general payments reported to CMS, 2019-2025
36 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2021: $11.92 · 2022: $68.71 · 2023: $318 · 2024: $450 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.01 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $203.25 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $148.94 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Janssen Biotech, INC. | $139.29 | 2019-2024 | Rybrevant, Imbruvica, Tecvayli |
| Heron Therapeutics, INC. | $137.11 | 2019-2024 | Zynrelef, Aponvie |
| Aveo Pharmaceuticals, INC. | $116.78 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $104.85 | 2023-2025 | |
| Abbvie INC. | $94.57 | 2023-2025 | Venclexta |
| Puma Biotechnology, INC. | $91.44 | 2019-2024 | |
| Glaxosmithkline, LLC. | $86.30 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $76.04 | 2024-2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $71.81 | 2019-2023 | |
| Stemline Therapeutics INC. | $64.63 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $60.08 | 2019 | |
| Pfizer INC. | $59.17 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $54.64 | 2019-2024 | Keytruda |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $49.85 | 2019-2023 | |
| Genmab U.S., INC. | $49.66 | 2024 | Epkinly |
| Adc Therapeutics America, INC. | $48.41 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.62 | 2019 | |
| Celgene Corporation | $36.08 | 2019-2023 | Reblozyl |
| Genentech USA, INC. | $35.04 | 2019-2025 | Tecentriq, Tecentriq Hybreza |
| E.R. Squibb & Sons, L.L.C. | $33.70 | 2019 | |
| Seagen INC. | $33.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.86 | 2023 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $22.79 | 2019 | |
| Astellas Pharma US INC | $22.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.89 | 2022 | |
| Array Biopharma INC | $20.60 | 2022 | |
| Tersera Therapeutics LLC | $20.32 | 2025 | Zoladex |
| Exelixis INC. | $16.37 | 2019 | |
| Pharmaessentia USA Corporation | $15.18 | 2023 | Besremi |
| Clovis Oncology, INC. | $14.20 | 2019 | |
| Lilly USA, LLC | $13.92 | 2019 | |
| Dendreon Pharmaceuticals LLC | $12.86 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Ferring Pharmaceuticals INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Unknown Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.